WSJ.com: Health Blog
Daiichi Sankyo and GlaxoSmithKline are teaming up to develop and market vaccines in Japan, the WSJ reports . Each company will hold a 50% share in the Japan Vaccine Co. venture, which will have an initial capitalization of $1.2 million and will begin...